Novel agents and strategies for overcoming EGFR TKIs resistanceReport as inadecuate

Novel agents and strategies for overcoming EGFR TKIs resistance - Download this document for free, or read online. Document in PDF available to download.

Experimental Hematology and Oncology

, 3:2

First Online: 11 January 2014Received: 08 October 2013Accepted: 31 December 2013DOI: 10.1186-2162-3619-3-2

Cite this article as: Niu, FY. & Wu, YL. Exp Hematol Oncol 2014 3: 2. doi:10.1186-2162-3619-3-2


Since the recognition of epidermal growth factor receptor EGFR as a therapeutic target, EGFR tyrosine kinase inhibitors TKIs have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment

The progression-free survival PFS of patients with EGFR mutations treated with EGFR TKIs is significantly prolonged compared with that of patients who underwent standard chemotherapy. However, all patients who initially respond to EGFR TKIs eventually develop acquired resistance AR. Many small molecule agents and monoclonal antibodies McAb targeting signaling pathways are potential therapeutic regimens for overcoming resistance, and various therapeutic strategies are used in clinical practice. Here we review the novel agents and therapeutic strategies for overcoming AR to EGFR TKIs.

KeywordsNon-small cell lung cancer EGFR TKI acquired resistance New agents IMPRESS ASPIRATION AbbreviationsEGFREpidermal growth factor receptor

TKIsTyrosine kinase inhibitors

PFSProgression-free survival

ARAcquired resistance

McAbMonoclonal antibodies


EMTEpithelial mesenchymal transition

SCLCSmall cell lung cancer

OSOverall survival

PRPartial response

CRComplete response

SDStable disease

HSP90Heat shock protein 90

RRResponse rate.

Electronic supplementary materialThe online version of this article doi:10.1186-2162-3619-3-2 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Fei-Yu Niu - Yi-Long Wu


Related documents